Use of principal component analysis in the evaluation of adherence to statin treatment: A method to determine a potential target population for public health intervention

Fundamental and Clinical Pharmacology

Volumn 25, Issue 4, 2011, Pages 528-533

  Latry, Philippe ^a   Martin Latry, Karin ^b,c   Labat, Anne ^a   Molimard, Mathieu ^b,c   Peter, Claude ^a  

^a Cnam TS   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM U657   (France)

Author keywords

Database; HMG CoA reductase inhibitors; Principal component analysis; Public health

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; COHORT ANALYSIS; FEMALE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PATIENT COMPLIANCE; PRESCRIPTION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REIMBURSEMENT; SEX RATIO;

AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; FEMALE; FRANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSURANCE, HEALTH, REIMBURSEMENT; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS; PUBLIC HEALTH PRACTICE; SEX FACTORS; TIME FACTORS;

EID: 79960009217     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00870.x     Document Type: Article

References (27)

1. Caspard H., Chan A.K., Walker A.M. Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin. Ther. (2005) 27 1639-1646.
2. Gislason G.H., Rasmussen J.N., Abildstrom S.Z. et al. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation (2007) 116 737-744.
3. Helin-Salmivaara A., Lavikainen P., Korhonen M. et al. Long-term persistence with statin therapy: a nationwide register study in Finland. Clin. Ther. (2008) 30 2228-2240.
4. Lachaine J., Rinfret S., Merikle E.P., Tarride J.E. Persistence and adherence to cholesterol lowering agents: evidence from Regie de l'Assurance Maladie du Quebec data. Am. Heart J. (2006) 152 164-169.
5. Mantel-Teeuwisse A.K., Goettsch W.G., Klungel O.H., de Boer A., Herings R.M. Long term persistence with statin treatment in daily medical practice. Heart (2004) 90 1065-1066.
6. Penning-van Beest F.J., Termorshuizen F., Goettsch W.G., Klungel O.H., Kastelein J.J., Herings R.M. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur. Heart J. (2007) 28 154-159.
7. Perreault S., Blais L., Lamarre D. et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br. J. Clin. Pharmacol. (2005) 59 564-573.
8. Poluzzi E., Strahinja P., Lanzoni M. et al. Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy. Eur. J. Clin. Pharmacol. (2008) 64 425-432.
9. Walley T., Folino-Gallo P., Schwabe U., van Ganse E. Variations and increase in use of statins across Europe: data from administrative databases. BMJ (2004) 328 385-386.
10. Martin K., Begaud B., Latry P., Miremont-Salame G., Fourrier A., Moore N. Differences between clinical trials and postmarketing use. Br. J. Clin. Pharmacol. (2004) 57 86-92.
11. Wei L., Ebrahim S., Bartlett C., Davey P.D., Sullivan F.M., MacDonald T.M. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ (2005) 330 821.
12. Wieringa N.F., de Graeff P.A., van der Werf G.T., Vos R. Cardiovascular drugs: discrepancies in demographics between pre- and post-registration use. Eur. J. Clin. Pharmacol. (1999) 55 537-544.
13. Ho P.M., Magid D.J., Shetterly S.M. et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am. Heart J. (2008) 155 772-779.
14. Perreault S., Dragomir A., Blais L. et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur. J. Clin. Pharmacol. (2009) 65 1013-1024.
15. Hanlon J., Pickett G. Public Health administration and practice, 8th edn. Times Mirror/Mosby, Saint Louis, 1984, p. 637.
16. Martin-Latry K., Begaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol. Drug Saf. (2010) 19, 256-265.
17. Falissard B. Comprendre et utiliser les statistiques dans les sciences de la vie. Masson, Paris, 1998.
18. Pagès J., Escoffier B. Analyses factorielles simples et multiples. Dunod, Paris, 2008.
19. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344 1383-1389.
20. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. (1998) 339 1349-1357.
21. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360 7-22.
22. Baigent C., Keech A., Kearney P. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet (2005) 366 1267-1278.
23. Sacks F.M., Pfeffer M.A., Moye L.A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. (1996) 335 1001-1009.
24. Serruys P.W., de Feyter P., Macaya C. et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 287 3215-3222.
25. Sever P.S., Dahlof B., Poulter N.R. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 361 1149-1158.
26. Shepherd J., Blauw G.J., Murphy M.B. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 360 1623-1630.
27. Shepherd J., Cobbe S., Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. (1995) 333 1301-1307.